Literature DB >> 33303971

Vascular remodeling by placenta-derived mesenchymal stem cells restores ovarian function in ovariectomized rat model via the VEGF pathway.

Jinki Cho1, Tae-Hee Kim2, Jin Seok1, Ji Hye Jun1, Hyeri Park1, Minyeoung Kweon3, Ja-Yun Lim4, Gi Jin Kim5.   

Abstract

Angiogenesis plays an important role in damaged organ or tissue and cell regeneration and ovarian development and function. Primary ovarian insufficiency (POI) is a prevalent pathology in women under 40. Conventional treatment for POI involves hormone therapy. However, due to its side effects, an alternative approach is desirable. Human mesenchymal stem cells (MSCs) from various sources restore ovarian function; however, they have many limitations as stem cell sources. Therefore, it is desirable to study the efficacy of placenta-derived MSCs (PD-MSCs), which possess many advantages over other MSCs, in a rat model of ovarian dysfunction. Here, we investigated the restorative effect of PD-MSCs on injured ovaries in ovariectomized (OVX) rats and the ability of intravenous transplantation (Tx) of PD-MSCs (5 × 105) to enhance ovarian vasculature and follicular development. ELISA analysis of serum revealed that compared to the non-transplantation (NTx) group, the Tx group showed significantly increased levels of anti-Müllerian hormone, follicle stimulating hormone, and estradiol (E2) (*P < 0.05). In addition, histological analysis showed more mature follicles and less atresia and restoration of expanded blood vessels in the ovaries of the OVX PD-MSC Tx group than those of the NTx group (*P < 0.05). Furthermore, folliculogenesis-related gene expression was also significantly increased in the PD-MSC Tx group (*P < 0.05). Vascular endothelial growth factor (VEGF) and VEGF receptor 2 expressions were increased in the ovaries of the OVX PD-MSC Tx group compared to the NTx group through PI3K/AKT/mTOR and GSK3β/β-catenin pathway activation. Interestingly, ex vivo cocultivation of damaged ovaries and PD-MSCs or treatment with recombinant VEGF (50 ng/ml) increased folliculogenic factors and VEGF signaling pathways. Notably, compared to recombinant VEGF, PD-MSCs significantly increased folliculogenesis and angiogenesis (*P < 0.05). These findings suggest that VEGF secreted by PD-MSCs promotes follicular development and ovarian function after OVX through vascular remodeling. Therefore, these results provide fundamental data for understanding the therapeutic effects and mechanism of stem cell therapy based on PD-MSCs and provide a theoretical foundation for their application for obstetrical and gynecological diseases, including infertility and menopause.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33303971      PMCID: PMC7892345          DOI: 10.1038/s41374-020-00513-1

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  49 in total

1.  Anti-Müllerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve.

Authors:  Norbert Gleicher; Andrea Weghofer; David H Barad
Journal:  Fertil Steril       Date:  2010-06-11       Impact factor: 7.329

2.  Diminished ovarian reserve, premature ovarian failure, poor ovarian responder--a plea for universal definitions.

Authors:  J Cohen; N Chabbert-Buffet; E Darai
Journal:  J Assist Reprod Genet       Date:  2015-10-13       Impact factor: 3.412

Review 3.  Ovarian aging and premature ovarian failure.

Authors:  Yavuz Emre Sükür; Içten Balık Kıvançlı; Batuhan Ozmen
Journal:  J Turk Ger Gynecol Assoc       Date:  2014-08-08

Review 4.  Dynamics of the ovarian reserve and impact of genetic and epidemiological factors on age of menopause.

Authors:  Emanuele Pelosi; Eleanor Simonsick; Antonino Forabosco; Jose Elias Garcia-Ortiz; David Schlessinger
Journal:  Biol Reprod       Date:  2015-04-22       Impact factor: 4.285

5.  Premature gonadal failure.

Authors:  C B Coulam
Journal:  Fertil Steril       Date:  1982-12       Impact factor: 7.329

6.  Hypoandrogenism in association with diminished functional ovarian reserve.

Authors:  Norbert Gleicher; Ann Kim; Andrea Weghofer; Vitaly A Kushnir; Aya Shohat-Tal; Emanuela Lazzaroni; Ho-Joon Lee; David H Barad
Journal:  Hum Reprod       Date:  2013-02-20       Impact factor: 6.918

7.  The endocrine and follicular growth dynamics throughout the menstrual cycle in women with consistently or variably elevated early follicular phase FSH compared with controls.

Authors:  C H de Koning; J McDonnell; A P N Themmen; F H de Jong; R Homburg; C B Lambalk
Journal:  Hum Reprod       Date:  2008-03-28       Impact factor: 6.918

8.  Profiling of differentially expressed microRNAs in premature ovarian failure in an animal model.

Authors:  Haixue Kuang; Dongwei Han; Jiaming Xie; Yongxin Yan; Ji Li; Pengling Ge
Journal:  Gynecol Endocrinol       Date:  2013-11-04       Impact factor: 2.260

Review 9.  Clinical practice. Primary ovarian insufficiency.

Authors:  Lawrence M Nelson
Journal:  N Engl J Med       Date:  2009-02-05       Impact factor: 91.245

10.  Adipose-derived stem cells improved mouse ovary function after chemotherapy-induced ovary failure.

Authors:  Min Sun; Shufang Wang; Yi Li; Ling Yu; Fang Gu; Changyong Wang; Yuanqing Yao
Journal:  Stem Cell Res Ther       Date:  2013-07-09       Impact factor: 6.832

View more
  11 in total

1.  UC-MSCs promote frozen-thawed ovaries angiogenesis via activation of the Wnt/β-catenin pathway in vitro ovarian culture system.

Authors:  Wenjuan Xu; Caiyun Wu; Xiaoqian Zhu; Jingjing Wu; Zhiguo Zhang; Zhaolian Wei; Yunxia Cao; Ping Zhou; Jianye Wang
Journal:  Stem Cell Res Ther       Date:  2022-07-15       Impact factor: 8.079

Review 2.  Amniotic stem cells as a source of regenerative medicine to treat female infertility.

Authors:  Aisha Naeem; Nikita Gupta; Usra Naeem; Mohamed A Elrayess; Chris Albanese
Journal:  Hum Cell       Date:  2022-10-17       Impact factor: 4.374

Review 3.  Is It Possible to Treat Infertility with Stem Cells?

Authors:  P Petric; E Vrtacnik-Bokal; M Stimpfel
Journal:  Reprod Sci       Date:  2021-04-08       Impact factor: 3.060

Review 4.  Mesenchymal Stem Cells in Preclinical Infertility Cytotherapy: A Retrospective Review.

Authors:  Zhuo Chang; Hui Zhu; Xueming Zhou; Yang Zhang; Bei Jiang; Shuoxi Li; Lu Chen; Xue Pan; Xiao-Ling Feng
Journal:  Stem Cells Int       Date:  2021-05-17       Impact factor: 5.443

5.  Metabolic Rewiring by Human Placenta-Derived Mesenchymal Stem Cell Therapy Promotes Rejuvenation in Aged Female Rats.

Authors:  Kyeoung-Hwa Kim; Kyung-Ah Lee
Journal:  Int J Mol Sci       Date:  2022-01-05       Impact factor: 5.923

Review 6.  Research Progress on the Treatment of Premature Ovarian Failure Using Mesenchymal Stem Cells: A Literature Review.

Authors:  Jing Wang; Wanru Liu; Dehai Yu; Zongxing Yang; Sijie Li; Xiguang Sun
Journal:  Front Cell Dev Biol       Date:  2021-12-13

7.  Targeted Next-Generation Sequencing Indicates a Frequent Oligogenic Involvement in Primary Ovarian Insufficiency Onset.

Authors:  Raffaella Rossetti; Silvia Moleri; Fabiana Guizzardi; Davide Gentilini; Laura Libera; Anna Marozzi; Costanzo Moretti; Francesco Brancati; Marco Bonomi; Luca Persani
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-04       Impact factor: 5.555

8.  Increased phosphatase regenerating liver-1 trigger vascular remodeling in injured ovary via platelet-derived growth factor signaling pathway.

Authors:  Hyeri Park; Jin Seok; Jun Hyeong You; Jae Yeon Kim; Ja-Yun Lim; Gi Jin Kim
Journal:  Stem Cell Res Ther       Date:  2022-03-07       Impact factor: 6.832

9.  Human amnion-derived mesenchymal stem cells improved the reproductive function of age-related diminished ovarian reserve in mice through Ampk/FoxO3a signaling pathway.

Authors:  Hanwen Liu; Chunyan Jiang; Boya La; Meng Cao; Song Ning; Jing Zhou; Zhengjie Yan; Chuyu Li; Yugui Cui; Xiang Ma; Meilian Wang; Li Chen; Youjia Yu; Feng Chen; Yuexin Zhang; Huimin Wu; Jiayin Liu; Lianju Qin
Journal:  Stem Cell Res Ther       Date:  2021-06-02       Impact factor: 6.832

10.  Appraisal of Experimental Methods to Manage Menopause and Infertility: Intraovarian Platelet-Rich Plasma vs. Condensed Platelet-Derived Cytokines.

Authors:  E Scott Sills; Samuel H Wood
Journal:  Medicina (Kaunas)       Date:  2021-12-21       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.